Arcus Biosciences Home | Pursuit of Curing Cancer

CLINICAL PIPELINE

Indication View

Molecule View

Indication

Study

Line & Regimen^a,b,c

Indication:

NSCLC

Study: 
                  
Line & Regimena,b,c : 
              WT 1L, PD-L1 ≥ 50%
                
                              dom + zim ± etruma
            
Phase 1 
Phase 1b 
              
Randomized/
Phase 2
Pivotal/
Phase 3
Study: 
                  
Line & Regimena,b,c : 

              WT 1L, PD-L1 ≥ 50%
                                  
                              dom + zim vs. zim vs. chemo
 
Phase 1 
Phase 1b 
              
Randomized/
Phase 2
Pivotal/
Phase 3
Study: 
                  
Line & Regimena,b,c : 

              Stage III, unresectable, PD-L1≥1%
                                  
                              dom + durvalumab vs. durvalumab
 
Phase 1 
Phase 1b 
              
Randomized/
Phase 2
Pivotal/
Phase 3
Study: 
                  
Line & Regimena,b,c : 

              1L
                                  
                              dom + zim + chemo vs. pembro + chemo
 
Phase 1 
Phase 1b 
              
Randomized/
Phase 2
Pivotal/
Phase 3

Indication:

mCRPC

Study:

Line & Regimen^a,b,c :

2L+
etruma + zim + doce

Phase 1

Phase 1b

Randomized/
Phase 2

Pivotal/
Phase 3

Indication:

CRC

Study: 
                  
Line & Regimena,b,c : 
              2L
                
                              etruma + zim + FOLFOX* vs. FOLFOX*
            
Phase 1 
Phase 1b 
              
Randomized/
Phase 2
Pivotal/
Phase 3
Study: 
                  
Line & Regimena,b,c : 

              3L
                                  
                              etruma + zim + FOLFOX* vs. rego
 
Phase 1 
Phase 1b 
              
Randomized/
Phase 2
Pivtotal/
Phase 3
Study: 
                  
Line & Regimena,b,c : 

              >3L
                                  
                              etruma combinations
 
Phase 1 
Phase 1b 
              
Randomized/
Phase 2
Pivtotal/
Phase 3

Indication:

PDAC

Study:

Line & Regimen^a,b,c :

1L
quemli + zim + gem/nab-pac

Phase 1

Phase 1b

Randomized/
Phase 2

Pivotal/
Phase 3

Study:

Line & Regimen^a,b,c :

2L
quemli + zim + gem/nab-pac

Phase 1

Phase 1b

Randomized/
Phase 2

Pivtotal/
Phase 3

Indication:

UPPER GI

Study:

Line & Regimen^a,b,c :

1L
dom + zim + FOLFOX*

Phase 1

Phase 1b

Randomized/
Phase 2

Pivotal/
Phase 3

Study:

Line & Regimen^a,b,c :

2L+
dom + zim

Phase 1

Phase 1b

Randomized/
Phase 2

Pivtotal/
Phase 3

Indication:

Advanced Malignancies

Study:

Line & Regimen^a,b,c :

2L+
AB521

Phase 1

Phase 1b

Randomized/
Phase 2

Pivotal/
Phase 3

Study:

Line & Regimen^a,b,c :

AB308 + zim

Phase 1

Phase 1b

Randomized/
Phase 2

Pivtotal/
Phase 3

Indication:

Healthy Participants

Study:

Line & Regimen^a,b,c :

AB521

Phase 1

Phase 1b

Randomized/
Phase 2

Pivotal/
Phase 3

Molecule^a,b,c :

Domvanalimab
(DOM)

FC-SILENT ANTI-TIGIT ANTIBODY

Indication:UPPER GI
Study:
                  
Line & Regimen:
                                                            dom + zim + FOLFOX*
            
Phase 1
Phase 1b
              
Phase 2
Phase 3
Indication:UPPER GI
Study:
                  
Line & Regimen:

              2L+
                                  
                              dom + zim
 
Phase 1
Phase 1b
              
Phase 2
Phase 3
Indication:NSCLC
Study:
                  
Line & Regimen:

              1L
                                  
                              dom + zim ± etruma
 
Phase 1
Phase 1b
              
Phase 2
Phase 3
Indication:NSCLC
Study:
                  
Line & Regimen:

              WT 1L, PD-L1 ≥ 50%
                                  
                              dom + zim vs. zim vs. chemo
 
Phase 1
Phase 1b
              
Phase 2
Phase 3
Indication:NSCLC
Study:
                  
Line & Regimen:

              Stage III, unresectable, PD-L1≥1%
                                  
                              dom + durvalumab vs. durvalumab
 
Phase 1
Phase 1b
              
Phase 2
Phase 3
Indication:NSCLC
Study:
                  
Line & Regimen:

              1L
                                  
                              dom + zim + chemo vs. pembro + chemo
 
Phase 1
Phase 1b
              
Phase 2
Phase 3

Molecule^a,b,c :

Etrumadenant
(ETRUMA)

Dual A_2a/A_2b Adenosine Receptor Antagonist Small Molecule

Indication:CRPC
Study:
                  
Line & Regimen:
              2L
                                  
                              etruma + zim + doce
            
Phase 1
Phase 1b
              
Phase 2
Phase 3
Indication:CRC
Study:
                  
Line & Regimen:

              2L
                                  
                              etruma + zim + FOLFOX* vs. FOLFOX*
 
Phase 1
Phase 1b
              
Phase 2
Phase 3
Indication:CRC
Study:
                  
Line & Regimen:

              3L
                                  
                              etruma + zim + FOLFOX* vs. rego
 
Phase 1
Phase 1b
              
Phase 2
Phase 3
Indication:CRC
Study:
                  
Line & Regimen:

              >3L
                                  
                              etruma combinations
 
Phase 1
Phase 1b
              
Phase 2
Phase 3
Indication:NSCLC
Study:
                  
Line & Regimen:

              1L
                                  
                              dom + zim ± etruma
 
Phase 1
Phase 1b
              
Phase 2
Phase 3

Etrumadenant: Dual A_2aR/A_2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
atezo: atezolizumab; bev: bevacizumab; carbo/pem: carboplatin/pemetrexed; doce: docetaxel; dom: domvanalimab; enza: enzalutamide; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; pembro: pembrolizumab; PLD: pegylated liposomal doxorubicin; quemli: quemliclustat; rego: regorafenib; SOC: standard of care; zim: zimberelimab;

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; GI=gastrointestinal; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; RCC=renal cell carcinoma

PARTNERSHIPS & COLLABORATIONS:

(a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

(b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

Astra Zeneca logo (c) Arcus and AstraZeneca are collaborating on PACIFIC-8, a registrational Phase 3 clinical trial, to evaluate domvanalimab plus durvalumab (Imfinzi®) in unresectable Stage 3 NSCLC with curative intent, where durvalumab is standard of care.

^*+/- biologic

COMBINING TO CURE^®

CLINICAL PIPELINE

DISCOVERY PIPELINE

Immuno-Oncology Target

Cancer Cell Intrinsic Target

COMBINING TO CURE®

CLINICAL PIPELINE

DISCOVERY PIPELINE

Immuno-Oncology Target

Cancer Cell Intrinsic Target

COMBINING TO CURE^®